Peking University Birth Cohort in Weifang (PKUBC-WF)
Peking University Birth Cohort in Weifang
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Haijun Wang, Ph.D
- Phone Number: 86-010-82805583
- Email: whjun1@bjmu.edu.cn
Study Contact Backup
- Name: Jue Liu, Ph.D
- Phone Number: 86-13426455743
- Email: jueliu@bjmu.edu.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Recruiting
- Peking University
-
Contact:
- Haijun Wang, Ph.D
- Phone Number: 86-010-82805583
- Email: whjun1@bjmu.edu.cn
-
Contact:
- Jue Liu, Ph.D
- Phone Number: 86-13426455743
- Email: jueliu@bjmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Pregnant woman
- Pregnant women, 6-13^+6 gestational weeks
- Resided in Weifang in the past half years and have no plan to move out after delivery
- Pregnant women who plan to have antenatal care and delivery in Weifang maternal&Child Hospital.
- Pregnant women who is willing to participate in this study with informed consent
Pregnant woman's husband
- His wife was eligible for enrollment
- He is the biological father of the child (his wife's current pregnancy)
- Pregnant women's husband who is willing to participate in this study with informed consent
Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.
5. Before the age of 8 years, his/her mother provided written informed consent. 6. After 8 years old, he/she agreed to continue this study and signed the informed consent.
Exclusion Criteria:
- Participants who cannot communicate normally.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Exposure group
Group with environmental, nutritional or lifestyle exposures
|
No intervention This is an observational study without any intervention
|
|
Non-exposed group
Group without any environmental, nutritional and lifestyle exposures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numbers and morbidity of participants with pregnancy complications
Time Frame: At delivery
|
Including gestational diabetes, gestational hypertension, anemia, and hypothyroidism during pregnancy
|
At delivery
|
|
Numbers and morbidity of participants with adverse pregnancy outcomes
Time Frame: At delivery
|
Including preterm birth, low birth weight, macrosomia, abortion, stillbirth, and birth defects.
|
At delivery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of diabetes mellitus in women
Time Frame: 6 weeks after delivery and 3 years after delivery
|
Measured by health professionals in clinic
|
6 weeks after delivery and 3 years after delivery
|
|
Incidence of hypertension in women
Time Frame: 6 weeks after delivery and 3 years after delivery
|
Measured by health professionals in clinic
|
6 weeks after delivery and 3 years after delivery
|
|
Weight in kilogram changes during childhood
Time Frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
Measured by health professionals in clinic
|
At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
|
Height in centimeter changes during childhood
Time Frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
Measured by health professionals in clinic
|
At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
|
Early Child development
Time Frame: Age at 6 weeks, 6 months and 12 months
|
Measured by Ages&Stages Questionnaires (ASQ).There are 6 questions in each of 5 domains of development: communication, gross motor, fine motor, problem-solving skills, and adaptive skills.
Each question is given a 10 (yes), 5 (sometimes), or 0 (not yet) score according to the parents' answers.
The sum scores (range from 0 to 300) and scores for each domain (range from 0 to 60) are calculated.
Chinese norms are available for each domain, and any domain screened <2 SDs below the mean is considered a positive screening.
A higher ASQ score means better development.
|
Age at 6 weeks, 6 months and 12 months
|
|
Incidence of child overweight and obesity
Time Frame: At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
Measured by health professionals in clinic
|
At birth and age at 6 weeks, 6 months, 12 months, 2 years, 3 years, 6 years, 9 years, 12 years, 15 years, and 17 years
|
|
Incidence of autism spectrum disorder in children
Time Frame: Age at 2 years, 3 years
|
Measured by The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F) and Autism Behavior Checklist (ABC) scales
|
Age at 2 years, 3 years
|
|
Incidence of attention-deficit/hyperactivity disorder in children
Time Frame: Age at 6 years
|
Measured by The Child Behavior Checklist (CBC) scale
|
Age at 6 years
|
|
Incidence of anxiety in adolescents
Time Frame: Age at 9 years, 12 years, 15 years, and 17 years
|
Measured by Social Anxiety Scale for Adolescents (SAS-A) scale
|
Age at 9 years, 12 years, 15 years, and 17 years
|
|
Incidence of depression in adolescents
Time Frame: Age at 9 years, 12 years, 15 years, and 17 years
|
Measured by Beck Depression Inventory-II (BDI-II) scale
|
Age at 9 years, 12 years, 15 years, and 17 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Haijun Wang, Ph.D, Peking University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Nutrition Disorders
- Female Urogenital Diseases and Pregnancy Complications
- Metabolic Diseases
- Overnutrition
- Body Weight
- Obstetric Labor, Premature
- Obstetric Labor Complications
- Pregnancy Complications
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Hematologic Diseases
- Overweight
- Hypertension
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Hemic and Lymphatic Diseases
- Premature Birth
- Obesity
- Diabetes, Gestational
- Hypertension, Pregnancy-Induced
- Anemia
Other Study ID Numbers
Other Study ID Numbers
- PKUBC-WF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.